Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
BMJ Open
; 12(3): e055821, 2022 Mar 03.
Article
in En
| MEDLINE
| ID: mdl-35241469
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Circulating Tumor DNA
Type of study:
Clinical_trials
Aspects:
Ethics
Limits:
Female
/
Humans
Language:
En
Journal:
BMJ Open
Year:
2022
Document type:
Article
Affiliation country:
Country of publication: